MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-015-1038-y

Медицинская библиотека · BMC cancer · 2015

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.

Aspinall Sherrie L, Good Chester B, Zhao Xinhua, Cunningham Francesca E, Heron Bernadette B, Geraci Mark, Passero Vida, Stone Roslyn A, Smith Kenneth J, Rogers Renee, Shields Jenna, Sartore Megan, Boyle D Patrick, Giberti Sherry, Szymanski John, Smith Doug, Ha Allen, Sessions Jolynn, Depcinski Shawn, Fishco Shane, Molina Irvin, Lepir Tanja, Jean Carmela, Cruz-Diaz Lymaris, Motta Jessica, Calderon-Vargas Rebeca, Maland Janelle, Keefe Sean, Tague Marshall, Leone Alice, Glovack Brian, Kaplan Blair, Cosgriff Sean, Kaster Lindsay, Tonnu-Mihara Ivy, Nguyen Kimmai, Carmichael Jenna, Clifford Linda, Lu Kan, Chatta Gurkamal

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS).

METHODS

Retrospective cohort of 367 patients diagnosed with stage III colon cancer in 2003-2008 and treated at 19 VA medical centers. Kaplan-Meier curves summarize 5-year OS and 3-year DFS by chemotherapy regimen and RDI, and multivariable Cox proportional hazards regression was used to model these associations.

RESULTS

5-fluorouracil/leucovorin (FU/LV) was the most commonly initiated regimen in 2003 (94.4%) and 2004 (62.7%); in 2005-2008, a majority of patients (60%-74%) was started on an oxaliplatin-based regimen. Median RDI was 82.3%. Receipt of >70% RDI was associated with better 5-year OS (p < 0.001) and 3-year DFS (P = 0.009) than was receipt of ≤70% RDI, with 5-year OS rates of 66.3% and 50.5%, respectively and 3-year DFS rates of 66.1% and 52.7%, respectively. In the multivariable analysis of 5-year OS, oxaliplatin + 5-FU/LV (versus 5-FU/LV) (HR = 0.55; 95% CI = 0.34-0.91), >70% RDI at the first year (HR = 0.58; 95% CI = 0.37-0.89) and married status (HR = 0.66; 95% CI = 0.45-0.97) were associated with significantly decreased risk of death, while age ≥75 (versus 55-64) (HR = 2.06; 95% CI = 1.25-3.40), Charlson Comorbidity Index (HR = 1.17; 95% CI = 1.06-1.30), T4 tumor status (versus T1/T2) (HR = 5.88; 95% CI = 2.69-12.9), N2 node status (HR = 1.68; 95% CI = 1.12-2.50) and bowel obstruction (HR = 2.32, 95% CI = 1.36-3.95) were associated with significantly increased risk. Similar associations were observed for DFS.

CONCLUSION

Patients with stage III colon cancer who received >70% RDI had improved 5-year OS. The association between RDI and survival needs to be examined in studies of adjuvant chemotherapy for colon cancer outside of the VA.

Для цитирования: Aspinall Sherrie L, Good Chester B, Zhao Xinhua, Cunningham Francesca E, Heron Bernadette B, Geraci Mark, Passero Vida, Stone Roslyn A, Smith Kenneth J, Rogers Renee, Shields Jenna, Sartore Megan, Boyle D Patrick, Giberti Sherry, Szymanski John, Smith Doug, Ha Allen, Sessions Jolynn, Depcinski Shawn, Fishco Shane, Molina Irvin, Lepir Tanja, Jean Carmela, Cruz-Diaz Lymaris, Motta Jessica, Calderon-Vargas Rebeca, Maland Janelle, Keefe Sean, Tague Marshall, Leone Alice, Glovack Brian, Kaplan Blair, Cosgriff Sean, Kaster Lindsay, Tonnu-Mihara Ivy, Nguyen Kimmai, Carmichael Jenna, Clifford Linda, Lu Kan, Chatta Gurkamal. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.. BMC cancer. 2015. DOI: 10.1186/s12885-015-1038-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.